Physician profile
Scott E Blinkoff
NPI 1699751545
$3,567.63
in general payments reported to CMS, 2019-2025
26 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $257 · 2021: $548 · 2022: $646 · 2023: $553 · 2024: $811 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,681.20 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Celgene Corporation | $382.51 | 2021-2024 | Zeposia |
| Pfizer INC. | $224.13 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $172.06 | 2021-2023 | |
| Glaukos Corporation | $140.90 | 2024 | Idose |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $120.00 | 2019 | |
| Ucb, INC. | $91.17 | 2019 | |
| Gilead Sciences, INC. | $70.59 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $55.94 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.19 | 2020-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $52.58 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $50.67 | 2024 | Dupixent |
| Medtronic, INC. | $48.43 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $47.52 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $40.15 | 2025 | Voquezna |
| Lilly USA, LLC | $34.00 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $32.82 | 2024 | Resmetirom |
| Biocon Biologics INC | $23.04 | 2024 | Hulio |
| Allergan, INC. | $22.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2025 | Entyvio |
| Qol Medical, LLC | $19.49 | 2024 | Sucraid |
| Celltrion USA INC. | $17.33 | 2025 | Vegzelma |
| Ardelyx, INC. | $14.82 | 2022 | |
| Braintree Laboratories, INC. | $13.72 | 2019 | |
| Redhill Biopharma INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Blinkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.